{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:46:08Z","timestamp":1795113968239,"version":"4.10.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Galantamine, an acetylcholinesterase (AChE) inhibitor used for symptomatic treatment of Alzheimer\u2019s disease (AD), shows substantial inter-individual variability in clinical response. Missense single nucleotide polymorphisms (SNPs) within the AChE active-site gorge may modulate inhibitor recognition. In this computational study, binding residues were defined from human AChE inhibitor co-crystal structures and cross-referenced with dbSNP missense variation, followed by in-silico predictions of variant impact, evolutionary conservation and folding stability, and assessment of ligand engagement by docking and molecular dynamics (MD) with MM\/GBSA binding-energy estimation. Using complexes containing galantamine (GNT) and a donepezil-like ligand (E20), 11 of 807 AChE missense variants overlapped binding-site residues, highlighting Phe294 (UniProt Phe326) and His447 (UniProt His479). ConSurf classified His447 as highly conserved, and MUpro predicted decreased folding stability for His447 substitutions. SwissDock docking indicated that His447Gln retains a plausible GNT binding pose and yielded the least favourable docking score among the tested variants, consistent with a potential reduction in binding strength. MD simulations (200 ns) of wild-type and His447Gln AChE\u2013GNT complexes supported preserved global structural integrity of the complex over the simulated timescale, while indicating local remodelling of the GNT binding microenvironment. MM\/GBSA estimates from terminal snapshots suggested a modestly less favourable theoretical binding free energy for His447Gln relative to wild-type (approximately 2.0\u00a0kcal mol\u207b\u00b9). Given that His447 is the catalytic triad histidine, such substitutions may have consequences for catalysis in addition to inhibitor binding; these in-silico findings require experimental validation using site-directed mutagenesis with kinetic and binding assays.<\/jats:p>","DOI":"10.1007\/s10822-026-00805-6","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:32:25Z","timestamp":1775701945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Single nucleotide polymorphisms affecting galantamine binding to acetylcholinesterase in Alzheimer\u2019s disease: a structural bioinformatics study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3920-1140","authenticated-orcid":false,"given":"Nadia","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-9963","authenticated-orcid":false,"given":"Bet\u00fcl","family":"Ak\u00e7esme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"805_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","volume":"19","author":"M Tzioras","year":"2023","unstructured":"Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL (2023) Synaptic degeneration in Alzheimer disease. Nat Rev Neurol 19:19\u201338. https:\/\/doi.org\/10.1038\/s41582-022-00749-z","journal-title":"Nat Rev Neurol"},{"key":"805_CR2","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.3390\/ijms232213954","volume":"23","author":"E Passeri","year":"2022","unstructured":"Passeri E, Elkhoury K, Morsink M et al (2022) Alzheimer\u2019s disease: treatment strategies and their limitations. Int J Mol Sci 23:13954. https:\/\/doi.org\/10.3390\/ijms232213954","journal-title":"Int J Mol Sci"},{"key":"805_CR3","first-page":"2709","volume-title":"Acetylcholinesterase inhibitors (Galantamine, Rivastigmine, and Donepezil). In: NeuroPsychopharmacotherapy","author":"GR Sridhar","year":"2022","unstructured":"Sridhar GR (2022) Acetylcholinesterase inhibitors (Galantamine, Rivastigmine, and Donepezil). In: NeuroPsychopharmacotherapy. Springer, Cham, pp 2709\u20132721"},{"key":"805_CR4","doi-asserted-by":"publisher","unstructured":"Chen Z-R, Huang J-B, Yang S-L et al (2022) Role of Cholinergic signaling in Alzheimer\u2019s disease. Molecules 27. https:\/\/doi.org\/10.3390\/molecules27061816","DOI":"10.3390\/molecules27061816"},{"key":"805_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.59298\/RIJRMS\/2025\/43109113","volume":"4","author":"NA Kemigisha","year":"2025","unstructured":"Kemigisha NA (2025) Exploring how acetylcholinesterase influences neural signaling beyond neurotransmitter hydrolysis and its paradoxical role in neurodegeneration. Res Invent J Res Med Sci 4:109\u2013113. https:\/\/doi.org\/10.59298\/RIJRMS\/2025\/43109113","journal-title":"Res Invent J Res Med Sci"},{"key":"805_CR6","doi-asserted-by":"publisher","unstructured":"Walczak-Nowicka \u0141J, Herbet M, Walczak-Nowicka \u0141J, Herbet M (2021) Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their pathogenesis. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22179290","DOI":"10.3390\/ijms22179290"},{"key":"805_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-0716-2573-6_13","volume-title":"Pharmacogenomics in Drug Discovery and Development","author":"R Cacabelos","year":"2022","unstructured":"Cacabelos R, Naidoo V, Mart\u00ednez-Iglesias O et al (2022) Pharmacogenomics of Alzheimer\u2019s disease: novel strategies for drug utilization and development. In: Yan Q (ed) Pharmacogenomics in Drug Discovery and Development. Springer US, New York, NY, pp 275\u2013387"},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"MT Manzari","year":"2021","unstructured":"Manzari MT, Shamay Y, Kiguchi H et al (2021) Targeted drug delivery strategies for precision medicines. Nat Rev Mater 6:351\u2013370. https:\/\/doi.org\/10.1038\/s41578-020-00269-6","journal-title":"Nat Rev Mater"},{"key":"805_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.nrleng.2018.03.022","volume":"37","author":"T Z\u00fa\u00f1iga Santamar\u00eda","year":"2022","unstructured":"Z\u00fa\u00f1iga Santamar\u00eda T, Yescas G\u00f3mez P, Fricke Galindo I et al (2022) Pharmacogenetic studies in Alzheimer disease. Neurol Engl Ed 37:287\u2013303. https:\/\/doi.org\/10.1016\/j.nrleng.2018.03.022","journal-title":"Neurol Engl Ed"},{"key":"805_CR10","doi-asserted-by":"publisher","unstructured":"Z\u00fa\u00f1iga-Santamar\u00eda T, P\u00e9rez-Aldana BE, Fricke-Galindo I et al (2025) Variants in neurotransmitter-related genes are associated with Alzheimer\u2019s disease risk and cognitive functioning but not short-term treatment response. Neurol Int 17. https:\/\/doi.org\/10.3390\/neurolint17050065","DOI":"10.3390\/neurolint17050065"},{"key":"805_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20:68\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(20)30412-9","journal-title":"Lancet Neurol"},{"key":"805_CR12","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.3390\/molecules29225349","volume":"29","author":"M Pappalardo","year":"2024","unstructured":"Pappalardo M, Sipala FM, Nicolosi MC et al (2024) Recent applications of in silico approaches for studying receptor mutations associated with human pathologies. Molecules 29:5349. https:\/\/doi.org\/10.3390\/molecules29225349","journal-title":"Molecules"},{"key":"805_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1515\/psr-2018-0158","volume":"8","author":"MKA Khan","year":"2023","unstructured":"Khan MKA, Akhtar S (2023) Novel drug design and bioinformatics: an introduction. Phys Sci Rev 8:1571\u20131591. https:\/\/doi.org\/10.1515\/psr-2018-0158","journal-title":"Phys Sci Rev"},{"key":"805_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40360-021-00512-y","volume":"22","author":"SM Ajjarapu","year":"2021","unstructured":"Ajjarapu SM, Tiwari A, Taj G et al (2021) Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer. BMC Pharmacol Toxicol 22:68. https:\/\/doi.org\/10.1186\/s40360-021-00512-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"805_CR15","doi-asserted-by":"publisher","unstructured":"Wang W, Liu H, Wen Y et al (2025) An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib. Front Pharmacol 16. https:\/\/doi.org\/10.3389\/fphar.2025.1619517","DOI":"10.3389\/fphar.2025.1619517"},{"key":"805_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40520-019-01359-4","volume":"33","author":"R Benfante","year":"2021","unstructured":"Benfante R, Di Lascio S, Cardani S, Fornasari D (2021) Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders. Aging Clin Exp Res 33:823\u2013834. https:\/\/doi.org\/10.1007\/s40520-019-01359-4","journal-title":"Aging Clin Exp Res"},{"key":"805_CR17","doi-asserted-by":"crossref","unstructured":"SwissDock (2024) : major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina | Nucleic Acids Research | Oxford Academic. https:\/\/academic.oup.com\/nar\/article\/52\/W1\/W324\/7660078. Accessed 16 Nov 2025","DOI":"10.1093\/nar\/gkae300"},{"key":"805_CR18","doi-asserted-by":"publisher","first-page":"W529","DOI":"10.1093\/nar\/gkq399","volume":"38","author":"H Ashkenazy","year":"2010","unstructured":"Ashkenazy H, Erez E, Martz E et al (2010) ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res 38:W529\u2013W533. https:\/\/doi.org\/10.1093\/nar\/gkq399","journal-title":"Nucleic Acids Res"},{"key":"805_CR19","doi-asserted-by":"publisher","first-page":"5823","DOI":"10.1021\/acs.jctc.8b00758","volume":"14","author":"TFD Silva","year":"2018","unstructured":"Silva TFD, Vila-Vi\u00e7osa D, Reis PBPS et al (2018) The impact of using single atomistic long-range cutoff schemes with the GROMOS 54A7 force field. J Chem Theory Comput 14:5823\u20135833. https:\/\/doi.org\/10.1021\/acs.jctc.8b00758","journal-title":"J Chem Theory Comput"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"185102","DOI":"10.1063\/5.0022135","volume":"153","author":"AS Kamenik","year":"2020","unstructured":"Kamenik AS, Handle PH, Hofer F et al (2020) Polarizable and non-polarizable force fields: Protein folding, unfolding, and misfolding. J Chem Phys 153:185102. https:\/\/doi.org\/10.1063\/5.0022135","journal-title":"J Chem Phys"},{"key":"805_CR21","doi-asserted-by":"publisher","unstructured":"Abraham M, Alekseenko A, Bergh C et al (2024) GROMACS 2023.5 Manual. https:\/\/doi.org\/10.5281\/ZENODO.11104865","DOI":"10.5281\/ZENODO.11104865"},{"key":"805_CR22","doi-asserted-by":"publisher","unstructured":"Gok M, Madrer N, Zorbaz T et al (2022) Altered levels of variant cholinesterase transcripts contribute to the imbalanced cholinergic signaling in Alzheimer\u2019s and Parkinson\u2019s disease. Front Mol Neurosci 15. https:\/\/doi.org\/10.3389\/fnmol.2022.941467","DOI":"10.3389\/fnmol.2022.941467"},{"key":"805_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/jnc.13928","volume":"142","author":"A Simchovitz","year":"2017","unstructured":"Simchovitz A, Heneka MT, Soreq H (2017) Personalized genetics of the cholinergic blockade of neuroinflammation. J Neurochem 142:178\u2013187. https:\/\/doi.org\/10.1111\/jnc.13928","journal-title":"J Neurochem"},{"key":"805_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00441-006-0239-8","volume":"326","author":"G Zimmerman","year":"2006","unstructured":"Zimmerman G, Soreq H (2006) Termination and beyond: acetylcholinesterase as a modulator of synaptic transmission. Cell Tissue Res 326:655\u2013669. https:\/\/doi.org\/10.1007\/s00441-006-0239-8","journal-title":"Cell Tissue Res"},{"key":"805_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.neuron.2016.09.006","volume":"91","author":"EC Ballinger","year":"2016","unstructured":"Ballinger EC, Ananth M, Talmage DA, Role LW (2016) Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron 91:1199\u20131218. https:\/\/doi.org\/10.1016\/j.neuron.2016.09.006","journal-title":"Neuron"},{"key":"805_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1749-6632.1999.tb09277.x","volume":"877","author":"M Sarter","year":"1999","unstructured":"Sarter M, Bruno JP, Turchi J (1999) Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann N Y Acad Sci 877:368\u2013382. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb09277.x","journal-title":"Ann N Y Acad Sci"},{"key":"805_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jbt.2570030404","volume":"3","author":"NMS Bakry","year":"1988","unstructured":"Bakry NMS, El-Rashidy AH, Eldefrawi AT, Eldefrawi ME (1988) Direct actions of organophosphate anticholinesterases on nicotinic and muscarinic acetylcholine receptors. J Biochem Toxicol 3:235\u2013259. https:\/\/doi.org\/10.1002\/jbt.2570030404","journal-title":"J Biochem Toxicol"},{"key":"805_CR28","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1021\/bi030206n","volume":"43","author":"D Kaplan","year":"2004","unstructured":"Kaplan D, Barak D, Ordentlich A et al (2004) Is Aromaticity essential for trapping the catalytic histidine 447 in human acetylcholinesterase? Biochemistry 43:3129\u20133136. https:\/\/doi.org\/10.1021\/bi030206n","journal-title":"Biochemistry"},{"key":"805_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s12551-022-01028-3","volume":"14","author":"J Konc","year":"2022","unstructured":"Konc J, Jane\u017ei\u010d D (2022) Protein binding sites for drug design. Biophys Rev 14:1413\u20131421. https:\/\/doi.org\/10.1007\/s12551-022-01028-3","journal-title":"Biophys Rev"},{"key":"805_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449\u2013461. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"},{"key":"805_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-011-1064-x","volume":"67","author":"C Chianella","year":"2011","unstructured":"Chianella C, Gragnaniello D, Maisano Delser P et al (2011) BCHE and CYP2D6 genetic variation in Alzheimer\u2019s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 67:1147\u20131157. https:\/\/doi.org\/10.1007\/s00228-011-1064-x","journal-title":"Eur J Clin Pharmacol"},{"key":"805_CR32","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/TCRM.S323387","volume":"17","author":"S Ruangritchankul","year":"2021","unstructured":"Ruangritchankul S, Chantharit P, Srisuma S, Gray LC (2021) Adverse drug reactions of acetylcholinesterase inhibitors in older people living with dementia: a comprehensive literature review. Ther Clin Risk Manag 17:927\u2013949. https:\/\/doi.org\/10.2147\/TCRM.S323387","journal-title":"Ther Clin Risk Manag"},{"key":"805_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.52711\/2321-5836.2025.00048","volume":"17","author":"TR Chandan","year":"2025","unstructured":"Chandan TR, Patil CD, Kundgir VB et al (2025) Pharmacogenomics and personalized medicine: a revolution in drug therapy. Res J Pharmacol Pharmacodyn 17:311\u2013318. https:\/\/doi.org\/10.52711\/2321-5836.2025.00048","journal-title":"Res J Pharmacol Pharmacodyn"},{"key":"805_CR34","doi-asserted-by":"publisher","unstructured":"Occhipinti M, Brambilla M, Galli G et al (2021) Evaluation of drug\u2014drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors. J Pers Med 11. https:\/\/doi.org\/10.3390\/jpm11050424","DOI":"10.3390\/jpm11050424"},{"key":"805_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/17460441.2023.2171984","volume":"18","author":"F Potlitz","year":"2023","unstructured":"Potlitz F, Link A, Schulig L (2023) Advances in the discovery of new chemotypes through ultra-large library docking. Expert Opin Drug Discov 18:303\u2013313. https:\/\/doi.org\/10.1080\/17460441.2023.2171984","journal-title":"Expert Opin Drug Discov"},{"key":"805_CR36","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.33011\/livecoms.4.1.1563","volume":"4","author":"JA Henderson","year":"2022","unstructured":"Henderson JA, Liu R, Harris JA et al (2022) A guide to the continuous constant pH molecular dynamics methods in amber and CHARMM [Article v1.0]. Living J Comput Mol Sci 4:1563. https:\/\/doi.org\/10.33011\/livecoms.4.1.1563","journal-title":"Living J Comput Mol Sci"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00805-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:32:30Z","timestamp":1775701950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00805-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00805-6","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"96"}}